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Multidrug resiatance and myelomonocytic
leukemia in Gaucher's disease
Gaucher's Disease (GD) is associated with an
increased risk of haematological malignancies. We
present a patient with GD who had a preleukaemic
phase prior to developing acute leukaemia. He
presented with a negative multidrug resistance
(MDR) profile that became positive at relapse.
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Gaucher's Disease (GD) is the most common lysoso-
mal storage disease. It results from a genetic deficiency
of the lysosomal enzyme ?- glucocerebrosidase causing
an abnormal accumulation of glucocerebrosides in
macrophages. Type ? GD is the commonest, defined by
the absence of neurologic involvement. Characteristic
features include hepatosplenomegaly, skeletal involve-
ment, elevated levels of serum ferritin, acid phosphatase,
angiotensin converting enzyme and chitotriosidase
enzyme. Treatment consists of enzyme replacement
therapy (ERT).
1 Haematological conditions reported in
GD include benign monoclonal gammopathy, multiple
myeloma, Hodgkin's and non Hodgkin's lymphoma and
all forms of leukaemia.
2
A male born in 1938 of Ashkenazi Jewish extraction
was diagnosed with type ? (genotype N370S/N370S) GD
in 1974 when he presented with splenomegaly and mild
thrombocytopenia. Bone marrow (BM) examination
revealed classical Gaucher cells and leucocyte assay con-
firmed a marked reduction in β-glucosidase enzyme
activity. In 1997 he presented with fatigue and bruising.
Haematological and biochemical data are presented in
Table 1. He was commenced on enzyme replacement
therapy (ERT) with cerezyme. This promptly improved
markers of GD activity with a reduction in spleen size,
decrease in plasma chitotriosidase enzyme activity to
251 nmol/h, but there was no significant improvement
in the pancytopenia. By January 1999 (Table 1) dysplas-
tic changes affecting all three cell lineages in addition to
infiltration by Gaucher cells was observed. A course of
intravenous immunoglobulin did not improve the
platelet count. He subsequently developed a blood pic-
ture compatible with chronic myelomonocytic
leukaemia (CMML). In September 2000 (Table 1) the BM
contained blasts cells (Figure 1) positive for CD117,
CD34, CD13, and CD14 confirming a diagnosis of
AML/M4. The plasma chitotriosidase activity rose from
late 1999 reaching 877 nmol/h in May 2000. He was
enrolled in the UKMRC AML14 trial and randomised to
receive DAT (daunorubicin, cytosine arabinoside,
thioguanine) plus PSC 833, an inhibitor of P-glycoprotein
(P-gp). He achieved a partial remission and proceeded to
a second course of combination chemotherapy. His mar-
row however failed to regenerate adequately. BM analy-
sis revealed a hypoplastic marrow with no residual
leukaemic cells. Subsequent cytogenetic analysis
revealed trisomy 8 confirming aggressive myelodyspla-
sia. The BM in November 2001 showed 10% blasts; his
disease progressed, he was treated palliatively and died
in March 2002.
Multidrug resistance (MDR) may arise when cytotoxic
agents are effluxed by malignant cells over-expressing P-
glycoprotein (P-gp). The MDR profile and drug sensitiv-
ity (IC50) on the patient's blast cells were investigated
by FACscan analysis and the cell viability assay (MTT)
respectively.
3 At presentation with AML, the blast cells
were rhodamine 123 (R123) efflux negative with normal
expression of P-gp, multidrug resistance protein (MRP1)
and lung resistance protein (LRP). IC50 studies showed
sensitivity to daunorubicin. Blast cells at relapse howev-
er, showed significant efflux of R123 with overexpres-
sion of P-gp (mean cell fluorescence, MCF 2.17 vs 0.94 at
presentation, overexpression MCF >1.1) reversible with
verapamil, a known inhibitor of P-gp. Expression of
MRP, LRP and the IC50 for daunorubicin did not signifi-
cantly change. The presentation cells were efflux
-ve, P-gp
-
ve and acquired a effux
+ve, P-gp
+ve phenotype on relapse
after treatment with daunorubicin, a well characterised
inducer of MDR. The plasma chitotriosidase enzyme
activity that was near normalised with ERT increased
coinciding with the onset of AML reflecting increased
turnover of cells imposing a burden on the reticulo-
endothelial system .
4
All four reported cases of acute leukaemia in GD have
developed a myelomonocytic type of leukaemia follow-
ing myelodysplasia.
2,5 Our patient is the first to have had
his MDR status studied and is the longest survivor. In
GD the abnormal accumulation of glucocerebroside in
BM, liver and spleen provides constant antigenic stimuli
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Figure 1 Bone marrow aspirate showing AML blasts cells.
Table 1 Biochemical and haematological characteristics.to the immune system which may predispose to lym-
phoid malignancy.
6 Similarly, monocytes that are defec-
tive due to excess glucocerebroside load could interfere
with normal immune regulation. Consequently all cases
of AML reported so far in GD are in the myelomonocyt-
ic form.
Although GD is rare its association with haematologi-
cal malignancy is reasonably strong. A retrospective
study found a 3.6 and 14.7 fold risk of cancer and
haematological malignancy respectively in Jewish
patients.
7 Alterations in ceramide metabolism may affect
P-gp mediated drug resistance and that inhibitors of glu-
cosylceramide synthesis may have a role in modulating
drug resistance phenotype.
8 We hope this report and dis-
cussion will increase awareness of the risk of haemato-
logical malignancy in GD, leading to earlier diagnosis
and management.
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